Project Grant R01CA287257
Award Date
9/5/24
Completion Date
8/31/29
Dollars Obligated
$1.4M
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60637, USA
Similar Awards
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), aims to evaluate the effectiveness of an intervention called "Current Together After Cancer" (CTAC) in improving knowledge, self-efficacy, and receipt of colorectal cancer surveillance among survivors. The $591,691 award will support a pragmatic randomized controlled trial to compare the CTAC intervention to static online cancer survivorship information in 654...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $696,852 to Harvard T.H. Chan School of Public Health to optimize a mobile messaging intervention to increase colorectal cancer (CRC) screening rates among patients at community health centers (CHCs). The project aims to use a two-phase process to first focus on maximizing patient engagement with a text message-based CRC screening campaign, and then use a factorial design...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), will support research to develop a targeted colorectal cancer (CRC) screening strategy for adults aged 45-49. The $224,099 grant, awarded on January 1, 2025, will enable the University of California, San Diego (UCSD) to conduct a pilot trial to assess the acceptability of CRC screening in this age group and identify effective strategies for screening implementation. It...
This $2,136,715 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) is focused on harnessing DNA methylation in peripheral blood to improve colorectal cancer prevention. The primary awardee, President and Fellows of Harvard College through its Harvard T.H. Chan School of Public Health, will lead the research effort. Key sub-awards have been made to Dana-Farber Cancer Institute and Boston University to contribute...
This federal Project Grant award of $622,913 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will fund a 5-year study to evaluate a multilevel intervention to increase colonoscopic follow-up after abnormal stool-based colorectal cancer screening in a community safety-net setting. The study will be conducted by the University of California, Los Angeles (UCLA) in partnership with the Northeast Valley Health Corporation (NEVHC), a...
This $181,640 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research led by a clinical scientist at The University of Texas MD Anderson Cancer Center. The primary objectives are to: Expand on the role of liquid biopsy biomarkers, specifically circulating tumor DNA (ctDNA) and extravesicle RNA (evRNA), to generate novel combination immunotherapy trials for colorectal and anal cancers. This includes analyzing samples from...
This Project Grant award of $1,958,708.00 from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify the burden and impact of false-positive results from lung cancer screening (LCS) using low-dose computed tomography. The primary objectives are to: 1) Identify attitudes, knowledge, and experiences with false-positive LCS results among patients and clinicians; 2) Determine patient-, exam-, radiologist-, and facility-level...
This $639,780 Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to characterize the early-stage colorectal cancer cell-free DNA (cfDNA) methylome landscape and develop a machine learning model for early detection of colorectal cancer. The awardee, The Leland Stanford Junior University, will generate cfDNA methylomes from patient samples to derive biomarker signatures, as well as build a classification model to detect...
This federal Project Grant award, with ID R37CA300540, was provided by the National Cancer Institute (CFDA 93.394, Cancer Detection and Diagnosis Research program) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The $564,414 award, effective from April 1, 2025 to March 31, 2030, supports research with two key objectives: 1) Developing and validating a predictive model using electronic health record data to accurately identify individuals at high risk for...